Subscribe to our Newsletters !!
HiGenoMB® Molecular Biology Division o
Telstar has developed a new sensor capable of moni
The virus outbreak i.e. monkey pox, has off late b
Micromeritics announced three significant new inve
Alembic Pharmaceuticals Limited (Alembic) today an
Following the success of the promotion and informa
Chromogenic culture media are used to isolate, ide
Emcure Pharmaceuticals Ltd (EPL) reported that it received an emergency Use Authorisation (EUA) approval from the Drug Controller General of India for the introduction of Molnupiravir the oral anti-viral that is under investigation, to treat mild COVID-19.
EPL plans to launch this drug with the name Lizuvira on India. Indian market.
“As the need for such a drug is imminent in the face of emerging challenges in COVID-19 treatment, EPL will endeavour to deliver Lizuvira (Molnupiravir) in a week’s time. A toll-free Helpline will be dedicated to help the doctors and patients access the product,” the company said in a statement.
Earlier this year, EPL was able to sign an agreement for licensing with Merck Sharpe Dohme (MSD) to produce and distribute Molnupiravir to India as well as over 100 countries of low and middle-income (LMICs). Molnupiravir is an oral anti-viral which blocks the replication of a variety of virus RNAs, including SARS-CoV-2 According to MSD.